8-K: ESSA Pharma Secures Amended Court Order for XenoTherapeutics Merger

ESSA Pharma Inc. received an amended Interim Order from the Supreme Court of British Columbia, approving key dates for its special meeting and court hearing related to the business combination with XenoTherapeutics Inc.

Summary

• ESSA Pharma Inc. received an amended Interim Order from the Supreme Court of British Columbia on September 25, 2025.
• The order pertains to the previously announced Business Combination Agreement with XenoTherapeutics Inc., under which Xeno will acquire all outstanding common shares of ESSA.
• The amended Interim Order approves the Special Meeting date for October 3, 2025, at 2:00 p.m. (Pacific Time), to be held online.
• The deadline to deliver notices of dissent is October 1, 2025.
• The Court hearing date for approval of the Arrangement is October 7, 2025.
• The deadline for responses from persons intending to attend the October 7th hearing is October 3, 2025.
• ESSA filed supplemental proxy materials reflecting previously announced revised terms of the Transaction on September 24, 2025.

Sentiment

Score: 6

Explanation: The filing provides a procedural update on a previously announced merger, confirming key dates and court approval for the process. This indicates steady progress towards the transaction's completion, which is generally positive for market certainty, though it doesn't introduce new financial performance data. The extensive list of risks is standard for such transactions.

Positives

• Receipt of an amended Interim Order from the Supreme Court of British Columbia indicates progress towards the completion of the Business Combination Agreement.
• Key dates for the Special Meeting and Court hearing have been approved, providing clarity on the transaction timeline.

Risks

• The completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and the satisfaction of other conditions to the completion of the Transaction.
• The potential for the date of the Special Meeting to change.
• Potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty or their respective directors or officers, including the effects of any outcomes related thereto.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.
• The risk that disruptions from the Transaction will harm the Company's business, including current plans and operations.
• The ability of the Company to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory and economic developments affecting the Company's business.
• The accuracy of the Company's financial projections.
• General business, market and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact the Company's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including but not limited to acts of terrorism, pandemics, outbreaks of war or hostilities, as well as the Company's response to any of the aforementioned factors.
• Significant transaction costs associated with the Transaction.
• The possibility that the Transaction may be more expensive to complete than anticipated, including as a result of unexpected factors or events.
• Competitive responses to the Transaction.
• Risks and uncertainties pertaining to the Company's business, including those set forth in the Company's Annual Report on Form 10-K dated December 17, 2024, and the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 11, 2025.

Future Outlook

The company anticipates the completion of the Transaction with XenoTherapeutics Inc. following the Special Meeting and Court approval, subject to various conditions and risks outlined in the filing and previous proxy statements.

Industry Context

This transaction represents a strategic shift for ESSA Pharma, moving from its previous focus on developing prostate cancer therapies to being acquired by XenoTherapeutics Inc., a non-profit biotechnology company focused on advancing xenotransplantation. This could signal an exit strategy for ESSA's prior business or a pivot towards new research areas under the XenoTherapeutics umbrella. XOMA Royalty Corporation is involved as a biotechnology royalty aggregator.

Corporate Governance

Legal Proceedings

• Potential litigation relating to the Transaction that could be instituted by or against the Company, Xeno, XOMA Royalty or their respective directors or officers.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.

Stakeholder Impact

• Shareholders, Optionholders, and Warrantholders: Will participate in the Special Meeting on October 3, 2025, to vote on the Transaction. They have a deadline of October 1, 2025, to deliver notices of dissent. The transaction involves Xeno acquiring all issued and outstanding common shares of ESSA.
• Employees: Face risks of disruptions from the Transaction harming the Company's business, including current plans and operations, and potential challenges in retaining and hiring key personnel.
• Customers and Suppliers: May experience potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.

Next Steps

• Hold the Special Meeting of securityholders on October 3, 2025, at 2:00 p.m. (Pacific Time).
• Attend the Court hearing for approval of the Arrangement on October 7, 2025.
• Work towards the completion of the Business Combination Agreement with XenoTherapeutics Inc.

Key Dates

Recommendation

The filing provides a procedural update on a previously announced merger, confirming that the necessary court approvals for the process are in place and key dates are set. This reduces uncertainty regarding the transaction's timeline but does not introduce new information that would fundamentally alter the valuation or strategic outlook beyond what was known when the merger was initially announced. Investors should hold pending the finalization of the transaction, as the current news confirms the process is on track without significant new positive or negative catalysts.

Keywords

ESSA Pharma, XenoTherapeutics, Business Combination, Merger, Acquisition, Biotechnology, Prostate Cancer, Xenotransplantation, NASDAQ: EPIX, Court Order, Special Meeting, Shareholder Vote